Program
Beclomethasone
Also written as “Beclomethasone dipropionate”, “Beclometasone/Formoterol/Glycopyrrolate” and “beclomethasone”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial · Graft vs Host Disease, led by 7 companies.
Drug pageBeclomethasone: every studyMany companies study it; this page follows only the 44 they lead. All 85 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiesi Farmaceuticiits history only | 220 open or running | phase 4since Oct 28, 2020 | Sep 29, 2006 | none ahead |
| Teva Pharmaceutical Industriesits history only | 140 open or running | phase 4since Oct 28, 2003 | Oct 28, 2003 | none ahead |
| Soligenixits history only | 30 open or running | phase 3since Jun 19, 2009 | Jun 19, 2009 | none ahead |
| Adamis Pharmaceuticalsits history only | 20 open or running | phase 3since Feb 6, 2019 | Feb 6, 2019 | none ahead |
| Enteron Pharmaceuticalsits history only | 10 open or running | phase 3since Oct 4, 2005 | Oct 4, 2005 | none ahead |
| Lunan Pharmaceutical Group | 11 open or running | phase 3since Jul 21, 2026 | Jul 21, 2026 | Jun 2028phase 3 · NCT07768891 |
| SOFARits history only | 10 open or running | phase 1since Apr 26, 2021 | Apr 26, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Lunan Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 21, 2026First study: phase 3 study in AsthmaFirst studyNCT07768891 · 416 planned · China
Ahead
- Jun 2028Primary completion: phase 3 study in AsthmaNCT07768891
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
The one study Lunan Pharmaceutical Group leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07768891Asthma · China | 3 | Recruiting | Jun 2028 | 416 |
How it is read
Names in the registry
- “Beclomethasone dipropionate”, 6 entries
- “Beclometasone/Formoterol/Glycopyrrolate”, 2 entries
- “beclomethasone”, 2 entries
- “beclomethasone dipropionate plus formoterol fumarate combination”, 2 entries
- “Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium”, 2 entries
Conditions, from the studies’ own filings
- Asthma, 25 studies
- Pulmonary Disease, Chronic Obstructive, 7 studies
- Rhinitis, Allergic, Seasonal, 3 studies
- Rhinitis, Allergic, Perennial, 3 studies
- Graft vs Host Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.